ASP Isotopes, Isotopia announce supply agreement for Gadolinium-160

ASP Isotopes (ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160, a critical precursor isotope for producing Terbium-161, an emerging medical isotope with significant potential in targeted radiotherapeutics. This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies. Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The collaboration combines ASP Isotopes’ expertise in large-scale isotope enrichment-previously demonstrated through its production of Ytterbium-176 -with Isotopia’s proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 and maintained weekly Tb-161 production for its clinical trials over the past two years.